Drugs / Metformin
Metformin
Drug Approved in the United StatesBiguanide antihyperglycemic agent·First approved·1995
- Registered trials
- 1304
- Ongoing
- 167/ 13%
- Completed
- 828
- Indications
- 1
Approved indications
| Indication |
|---|
| Type 2 diabetes mellitus (adjunct to diet and exercise) |
Clinical trial landscape
1304 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 4 | 305 | 28 | 198 | |
| Phase 3 | 275 | 30 | 197 | |
| Phase 2 | 253 | 40 | 131 | |
| Phase 1 | 181 | 18 | 149 | |
| Not applicable | 145 | 24 | 77 | |
| Phase 2/3 | 45 | 10 | 23 | |
| Early Phase 1 | 37 | 8 | 20 | |
| Unknown | 32 | 3 | 16 | |
| Phase 1/2 | 31 | 6 | 17 | |
| All phases | 1304 | 167 | 828 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity with increased peripheral glucose uptake/utilization.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.